Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.
You may also be interested in...
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates